



Nexstim Plc: Managers' Transactions, Laine

Company Announcement, Helsinki, 2 October 2026 at 02:00 PM (EEST)

Nexstim Plc ("**Nexstim**" or "**Company**") announces managers' transactions as follows:

Person subject to the notification requirement

Name: Jarmo Laine

Position: Other senior manager

Issuer: Nexstim Oyj

LEI: 743700S7ZI0LNMHZ6Y27

Notification type: INITIAL NOTIFICATION

Reference number: 175084/6/6

Transaction date: 2026-09-24

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000506811

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 1000 Unit price: 9.51 EUR

Aggregated transactions (1):

Volume: 1000 Volume weighted average price: 9.51 EUR

Transaction date: 2026-09-25

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000506811

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 1000 Unit price: 9.55 EUR

Aggregated transactions (1):

Volume: 1000 Volume weighted average price: 9.55 EUR

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com



The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com.